Completed PHASE2 INTERVENTIONAL 4-arm NCT02288559

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

Sponsor: Genentech, Inc.

Conditions Geographic Atrophy

Interventions Lampalizumab Sham

Updated 15 times since 2017 Last updated: Sep 23, 2019 Started: Mar 30, 2015 Primary completion: Jun 2, 2017 Completion: Jun 2, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Geographic Atrophy and is currently completed. Genentech, Inc. leads this study, which shows 15 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Oct 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 10 earlier versions

Mar 2019 — Oct 2019 [monthly]

Completed PHASE2
Nov 2018 — Mar 2019 [monthly]

Completed PHASE2
Jul 2018 — Nov 2018 [monthly]

Completed PHASE2
Jun 2018 — Jul 2018 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Oct 2017 — Dec 2017 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Aug 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE2
Jun 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Albuquerque, United States , Asheville, United States , Baltimore, United States , Boynton Beach, United States , Campbell, United States , Charleston, United States , Charlotte, United States , Chicago, United States , Cincinnati, United States and 26 more locations